US approves Gilead's twice-yearly injection to prevent HIV / Photo: JUSTIN SULLIVAN - GETTY IMAGES NORTH AMERICA/AFP
-
Nobel winner Machado suffered vertebra fracture leaving Venezuela
-
Stock market optimism returns after tech sell-off
-
Iran Nobel winner unwell after 'violent' arrest: supporters
-
'Angry' Louvre workers' strike shuts out thousands of tourists
-
EU faces key summit on using Russian assets for Ukraine
-
Maresca committed to Chelsea despite outburst
-
Trapped, starving and afraid in besieged Sudan city
-
Messi mania peaks in India's pollution-hit capital
-
Wales captains Morgan and Lake sign for Gloucester
-
Serbian minister indicted over Kushner-linked hotel plan
-
Eurovision 2026 will feature 35 countries: organisers
-
Cambodia says Thailand bombs province home to Angkor temples
-
US-Ukrainian talks resume in Berlin with territorial stakes unresolved
-
Small firms join charge to boost Europe's weapon supplies
-
Driver behind Liverpool football parade 'horror' warned of long jail term
-
German shipyard, rescued by the state, gets mega deal
-
Flash flood kills dozens in Morocco town
-
'We are angry': Louvre Museum closed as workers strike
-
Australia to toughen gun laws as it mourns deadly Bondi attack
-
Stocks diverge ahead of central bank calls, US data
-
Wales captain Morgan to join Gloucester
-
UK pop star Cliff Richard reveals prostate cancer treatment
-
Mariah Carey to headline Winter Olympics opening ceremony
-
Indonesia to revoke 22 forestry permits after deadly floods
-
Louvre Museum closed as workers strike
-
Spain fines Airbnb 64 mn euros for posting banned properties
-
Japan's only two pandas to be sent back to China
-
Zelensky, US envoys to push on with Ukraine talks in Berlin
-
Australia to toughen gun laws after deadly Bondi shootings
-
Lyon poised to bounce back after surprise Brisbane omission
-
Australia defends record on antisemitism after Bondi Beach attack
-
US police probe deaths of director Rob Reiner, wife as 'apparent homicide'
-
'Terrified' Sydney man misidentified as Bondi shooter
-
Cambodia says Thai air strikes hit home province of heritage temples
-
EU-Mercosur trade deal faces bumpy ride to finish line
-
Inside the mind of Tolkien illustrator John Howe
-
Mbeumo faces double Cameroon challenge at AFCON
-
Tongue replaces Atkinson in only England change for third Ashes Test
-
England's Brook vows to rein it in after 'shocking' Ashes shots
-
Bondi Beach gunmen had possible Islamic State links, says ABC
-
Lakers fend off Suns fightback, Hawks edge Sixers
-
Louvre trade unions to launch rolling strike
-
Asian markets drop with Wall St as tech fears revive
-
North Korean leader's sister sports Chinese foldable phone
-
Iran's women bikers take the road despite legal, social obstacles
-
Civilians venture home after militia seizes DR Congo town
-
Countdown to disclosure: Epstein deadline tests US transparency
-
Desperate England looking for Ashes miracle in Adelaide
-
Far-right Kast wins Chile election in landslide
-
What we know about Australia's Bondi Beach attack
NYSE - LSE
| SCS | 0.12% | 16.14 | $ | |
| BCE | 0.62% | 23.54 | $ | |
| BCC | -0.72% | 75.96 | $ | |
| NGG | 1.17% | 75.82 | $ | |
| GSK | 0.93% | 49.27 | $ | |
| RBGPF | -4.49% | 77.68 | $ | |
| RIO | -0.17% | 75.53 | $ | |
| CMSC | -0.04% | 23.29 | $ | |
| JRI | 0.06% | 13.575 | $ | |
| RYCEF | 1.48% | 14.82 | $ | |
| CMSD | 0.32% | 23.325 | $ | |
| BTI | 0.9% | 57.62 | $ | |
| AZN | 1.43% | 91.13 | $ | |
| VOD | 1.14% | 12.735 | $ | |
| RELX | 2.29% | 41.325 | $ | |
| BP | -0.03% | 35.25 | $ |
US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV, a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.
Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But because they typically require taking a daily pill, they have struggled to make a significant dent in global infections.
"This is a historic day in the decades-long fight against HIV," said Daniel O'Day, Gilead's chairman and chief executive officer, in a statement.
Lenacapavir, marketed under the brand name Yeztugo, has been shown in clinical trials to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents -- making it functionally akin to a powerful vaccine.
But optimism may be tempered by the drug's expected eye-watering price tag.
While the company has not disclosed specifics, analysts estimate the US launch price could be as high as $25,000 per year.
Activists are calling for the price to be slashed to $25 per person annually to help end the HIV pandemic.
The approval also comes as President Donald Trump's administration has slashed funding for HIV treatment and prevention programs both overseas and within the United States.
E.Ramalho--PC
